Immunotherapeutic Strategies for Passive Immunization Against Pseudomonas aeruginosa

  • L. Saravolatz
  • J. Kilborn
  • J. Pennington


The advances of medical technology have resulted in a population of patients at increased risk of serious infections from opportunistic pathogens. Despite the availability of major new antimicrobial agents with in vitro activity, Pseudomonas aeruginosa has emerged as the most common cause of hospital-acquired pneumonia with a mortality of 50%–100%. A recent publication of bacteremia from 1984 to 1987 revealed a mortality of 51.1% at the time of discharge [1]. This mortality is approximately twofold higher than with other gram-negative pathogens or with gram-positive bacterial infections.


Pseudomonas Aeruginosa Passive Immunization Immunotherapeutic Strategy Intravenous Immune Globulin Passive Immunotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Roberts FJ, Geere IW, Coldman A (1991) A Three-year Study of Positive Blood Cultures with Emphasis on Prognosis. Rev Infect Dis 13:34–46PubMedCrossRefGoogle Scholar
  2. 2.
    Anonymous (1984) Nosocomial infection surveillance: CDC morbidity and mortality weekly report, vol 35, pp. 17ss–29ssGoogle Scholar
  3. 3.
    Pennington JE (1990) Pseudomonas aeruginosa vaccines and immunotherapy. Infect Dis Clin North Am 4/2:259–270Google Scholar
  4. 4.
    Collins MS, Roby RE (1984) Protective activity of an intravenous immune globulin (human) enriched in antibody against lipopolysaccharide antigens of Pseudomonas aeruginosa. Am J Med 76: 168–174PubMedCrossRefGoogle Scholar
  5. 5.
    Pennington JE (1979) Lipopolysaccharide Pseudomonas vaccine: efficacy against pulmonary infection with Pseudomonas aeruginosa. J Infect Dis 140:73–80PubMedCrossRefGoogle Scholar
  6. 6.
    Pennington JE, Peir GB, Small GJ (1986) Efficacy of intravenous immune globulin for treatment of experimental Pseudomonas aeruginosa. J Crit Care 1:4–10CrossRefGoogle Scholar
  7. 7.
    Young LS (1972) Human immunity to Pseudomonas aeruginosa IL Relationship between heat-stable Opsonins and type-specific lipopolysaccharides. J Infect Dis 126:277–287PubMedCrossRefGoogle Scholar
  8. 8.
    Alexander JW, Fisher MW (1974) Immunization against Pseudomonas in infection after thermal injury. J Infect Dis 130 [Suppl]:S152–S158CrossRefGoogle Scholar
  9. 9.
    Pennington JE, Small GJ (1987) Passive immune therapy for experimental Pseudomonas aeruginosa pneumonia in the neutropenic host. J Infect Dis 155:973–978PubMedCrossRefGoogle Scholar
  10. 10.
    Pennington JE, Small GJ, Lostrom ME et al. (1986) Polyclonal and monoclonal antibody therapy for experimental Pseudomonas aeruginosa pneumonia. Infect Immun 54:239–244PubMedGoogle Scholar
  11. 11.
    Sadoff JC, Wright DC, Futrovsky S et al. (1986) Characterization of mouse monoclonal antibodies directed against Pseudomonas aeruginosa lipopolysaccharides. Antibiot Chemother 36:134–146Google Scholar
  12. 12.
    Sawada S, Suzuki M, Kawamura T et al. (1984) Protection against infection with Pseudomonas aeruginosa by passive transfer of monoclonal antibodies to lipopolysaccharides and outer membrane proteins. J Infect Dis 150:570–576PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag, Berlin Heidelberg 1993

Authors and Affiliations

  • L. Saravolatz
    • 1
  • J. Kilborn
    • 1
  • J. Pennington
    • 2
  1. 1.Henry Ford HospitalDetroitUSA
  2. 2.Cutter LaboratoriesBerkeleyUSA

Personalised recommendations